Teladoc sets record with 100,000 patient visits in November

Telemedicine is one of the fastest growing segments in the healthcare industry as providers and patients become more comfortable with the concept of remote care.

Teladoc has been especially competitive in recent with months by providing more than 100,000 patient visits in the month of November, a company record according to a statement.

The Purchase, New York-based company's growth is in line with the American Telemedicine Association's prediction that there will be 1.25 million telemedicine visits in 2016.

In addition to the monthly record, the telehealth provider also set a daily mark with 4,158 visits, roughly one visit every 8.5 seconds.

Teladoc attributes its growth in November to an increase in utilization from existing members, as well as new members that have joined since it expanded its clinical services.

“This new milestone ... further substantiates that Teladoc has the scalable platform, clinical expertise and member support needed to effectively manage the increased volume as more and more consumers are engaging with us,” said Stephany Verstraete, chief marketing officer of Teladoc, in a statement. “Our innovative approach to driving adoption is proving effective in shifting member mindset; members are embracing Teladoc as a valued care option.”

Teladoc is one of the most popular telemedicine platforms because of its member engagement initiatives, broad network of U.S. board-certified physicians and its ongoing expansion into clinical specialties, the company said. As of press time, Teladoc had more than 17 million members and 3,100 board-certified physicians in its network.

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup